JJBC
CRSP icon

James J. Burns & Company’s CRISPR Therapeutics CRSP Stock Holding History

James J. Burns & Company’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$210K Buy
+3,855
New +$203K 0.02% 153

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

James J. Burns & Company's CRSP Position: Q2 2026 in Review

James J. Burns & Company opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 3,855 shares worth $210K. The stake represents 0.02% of the portfolio and ranks #153 among its holdings.

521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • James J. Burns & Company held 3,855 shares of CRISPR Therapeutics worth $210K as of Q2 2026.
  • CRISPR Therapeutics was a new James J. Burns & Company position in Q2 2026.
  • CRISPR Therapeutics made up 0.02% of James J. Burns & Company's portfolio in Q2 2026, its #153 holding.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on James J. Burns & Company's 13F filing for Q2 2026, filed 6 Aug 2026.